144 related articles for article (PubMed ID: 29149761)
1. Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with MET mutations or amplification. EORTC 90101 CREATE trial.
Schöffski P; Wozniak A; Escudier B; Rutkowski P; Anthoney A; Bauer S; Sufliarsky J; van Herpen C; Lindner LH; Grünwald V; Zakotnik B; Lerut E; Debiec-Rychter M; Marréaud S; Lia M; Raveloarivahy T; Collette S; Albiges L
Eur J Cancer; 2017 Dec; 87():147-163. PubMed ID: 29149761
[TBL] [Abstract][Full Text] [Related]
2. Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma.
Choueiri TK; Vaishampayan U; Rosenberg JE; Logan TF; Harzstark AL; Bukowski RM; Rini BI; Srinivas S; Stein MN; Adams LM; Ottesen LH; Laubscher KH; Sherman L; McDermott DF; Haas NB; Flaherty KT; Ross R; Eisenberg P; Meltzer PS; Merino MJ; Bottaro DP; Linehan WM; Srinivasan R
J Clin Oncol; 2013 Jan; 31(2):181-6. PubMed ID: 23213094
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of Savolitinib vs Sunitinib in Patients With MET-Driven Papillary Renal Cell Carcinoma: The SAVOIR Phase 3 Randomized Clinical Trial.
Choueiri TK; Heng DYC; Lee JL; Cancel M; Verheijen RB; Mellemgaard A; Ottesen LH; Frigault MM; L'Hernault A; Szijgyarto Z; Signoretti S; Albiges L
JAMA Oncol; 2020 Aug; 6(8):1247-1255. PubMed ID: 32469384
[TBL] [Abstract][Full Text] [Related]
4. Long-term efficacy of crizotinib in a metastatic papillary renal carcinoma with MET amplification: a case report and literature review.
Rochigneux P; Thomassin-Piana J; Laibe S; Brunelle S; Salem N; Escudier B; Vassal G; Gravis G
BMC Cancer; 2018 Nov; 18(1):1159. PubMed ID: 30466410
[TBL] [Abstract][Full Text] [Related]
5. A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial.
Pal SK; Tangen C; Thompson IM; Balzer-Haas N; George DJ; Heng DYC; Shuch B; Stein M; Tretiakova M; Humphrey P; Adeniran A; Narayan V; Bjarnason GA; Vaishampayan U; Alva A; Zhang T; Cole S; Plets M; Wright J; Lara PN
Lancet; 2021 Feb; 397(10275):695-703. PubMed ID: 33592176
[TBL] [Abstract][Full Text] [Related]
6. MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib.
Lennerz JK; Kwak EL; Ackerman A; Michael M; Fox SB; Bergethon K; Lauwers GY; Christensen JG; Wilner KD; Haber DA; Salgia R; Bang YJ; Clark JW; Solomon BJ; Iafrate AJ
J Clin Oncol; 2011 Dec; 29(36):4803-10. PubMed ID: 22042947
[TBL] [Abstract][Full Text] [Related]
7. Phase II and Biomarker Study of Cabozantinib in Metastatic Triple-Negative Breast Cancer Patients.
Tolaney SM; Ziehr DR; Guo H; Ng MR; Barry WT; Higgins MJ; Isakoff SJ; Brock JE; Ivanova EV; Paweletz CP; Demeo MK; Ramaiya NH; Overmoyer BA; Jain RK; Winer EP; Duda DG
Oncologist; 2017 Jan; 22(1):25-32. PubMed ID: 27789775
[TBL] [Abstract][Full Text] [Related]
8. Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer.
Lam ET; Ringel MD; Kloos RT; Prior TW; Knopp MV; Liang J; Sammet S; Hall NC; Wakely PE; Vasko VV; Saji M; Snyder PJ; Wei L; Arbogast D; Collamore M; Wright JJ; Moley JF; Villalona-Calero MA; Shah MH
J Clin Oncol; 2010 May; 28(14):2323-30. PubMed ID: 20368568
[TBL] [Abstract][Full Text] [Related]
9. Phase II clinical and exploratory biomarker study of dacomitinib in recurrent and/or metastatic esophageal squamous cell carcinoma.
Kim HS; Kim SM; Kim H; Pyo KH; Sun JM; Ahn MJ; Park K; Keam B; Kwon NJ; Yun HJ; Kim HG; Chung IJ; Lee JS; Lee KH; Kim DJ; Lee CG; Hur J; Chung H; Park JC; Shin SK; Lee SK; Kim HR; Moon YW; Lee YC; Kim JH; Paik S; Cho BC
Oncotarget; 2015 Dec; 6(42):44971-84. PubMed ID: 26462025
[TBL] [Abstract][Full Text] [Related]
10. Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration.
Drilon A; Clark JW; Weiss J; Ou SI; Camidge DR; Solomon BJ; Otterson GA; Villaruz LC; Riely GJ; Heist RS; Awad MM; Shapiro GI; Satouchi M; Hida T; Hayashi H; Murphy DA; Wang SC; Li S; Usari T; Wilner KD; Paik PK
Nat Med; 2020 Jan; 26(1):47-51. PubMed ID: 31932802
[TBL] [Abstract][Full Text] [Related]
11. Phase 2 trial of crizotinib in Japanese patients with advanced NSCLC harboring a MET gene alteration: a Co-MET study.
Nosaki K; Yoh K; Toyozawa R; Horinouchi H; Morise M; Ohashi K; Murakami H; Satouchi M; Sakakibara-Konishi J; Yano S; Okumura F; Matsumoto S; Shimokawa M; Seto T; Goto K
Int J Clin Oncol; 2024 May; ():. PubMed ID: 38758397
[TBL] [Abstract][Full Text] [Related]
12. MET expression and copy number status in clear-cell renal cell carcinoma: prognostic value and potential predictive marker.
Macher-Goeppinger S; Keith M; Endris V; Penzel R; Tagscherer KE; Pahernik S; Hohenfellner M; Gardner H; Grüllich C; Schirmacher P; Roth W
Oncotarget; 2017 Jan; 8(1):1046-1057. PubMed ID: 27894094
[TBL] [Abstract][Full Text] [Related]
13. Mesenchymal-Epithelial Transition Kinase Inhibitor Therapy in Patients with Advanced Papillary Renal-Cell Carcinoma: A Systematic Review and Meta-Analysis.
Moraes FCA; Vilbert M; Alves VFC; de Oliveira Almeida G; Priantti JN; Madeira T; Stecca C; Fernandes MR; Dos Santos NPC
Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139411
[TBL] [Abstract][Full Text] [Related]
14. Phase II study investigating the efficacy and safety of glesatinib (MGCD265) in patients with advanced NSCLC containing MET activating alterations.
Hong DS; Cappuzzo F; Chul Cho B; Dowlati A; Hussein M; Kim DW; Percent I; Christensen JG; Morin J; Potvin D; Faltaos D; Tassell V; Der-Torossian H; Chao R
Lung Cancer; 2024 Apr; 190():107512. PubMed ID: 38417277
[TBL] [Abstract][Full Text] [Related]
15. A first-in-human study of AMG 208, an oral MET inhibitor, in adult patients with advanced solid tumors.
Hong DS; Rosen P; Lockhart AC; Fu S; Janku F; Kurzrock R; Khan R; Amore B; Caudillo I; Deng H; Hwang YC; Loberg R; Ngarmchamnanrith G; Beaupre DM; Lee P
Oncotarget; 2015 Jul; 6(21):18693-706. PubMed ID: 26155941
[TBL] [Abstract][Full Text] [Related]
16. Hereditary papillary renal cell carcinoma.
Jacoba IM; Lu Z
Semin Diagn Pathol; 2024 Jan; 41(1):28-31. PubMed ID: 38135585
[TBL] [Abstract][Full Text] [Related]
17. Multicenter Phase II Trial of the WEE1 Inhibitor Adavosertib in Refractory Solid Tumors Harboring
Fu S; Yao S; Yuan Y; Previs RA; Elias AD; Carvajal RD; George TJ; Yuan Y; Yu L; Westin SN; Xing Y; Dumbrava EE; Karp DD; Piha-Paul SA; Tsimberidou AM; Ahnert JR; Takebe N; Lu K; Keyomarsi K; Meric-Bernstam F
J Clin Oncol; 2023 Mar; 41(9):1725-1734. PubMed ID: 36469840
[TBL] [Abstract][Full Text] [Related]
18. A challenging frontier - the genomics and therapeutics of nonclear cell renal cell carcinoma.
Patel HV; Srivastava A; Srinivasan R; Singer EA
Curr Opin Oncol; 2021 May; 33(3):212-220. PubMed ID: 33818540
[TBL] [Abstract][Full Text] [Related]
19. Phase II Study of Erdafitinib in Patients With Tumors With
Gong J; Mita AC; Wei Z; Cheng HH; Mitchell EP; Wright JJ; Ivy SP; Wang V; Gray RC; McShane LM; Rubinstein LV; Patton DR; Williams PM; Hamilton SR; Alva AS; Tricoli JV; Conley BA; Arteaga CL; Harris LN; O'Dwyer PJ; Chen AP; Flaherty KT
JCO Precis Oncol; 2024 Apr; 8():e2300406. PubMed ID: 38603651
[TBL] [Abstract][Full Text] [Related]
20. Tislelizumab combined with apatinib in the treatment of advanced renal clear cell carcinoma: a case report.
Qu F; Wu S; Zhang J
Anticancer Drugs; 2022 Jan; 33(1):e834-e839. PubMed ID: 34459463
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
